Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma
Condition(s):Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IIID MelanomaLast Updated:February 21, 2024Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IIID MelanomaLast Updated:February 21, 2024Not yet recruiting
Condition(s):Healthy AdultLast Updated:December 15, 2023Completed
Condition(s):Acute Myeloid Leukemia; Acute Myeloid Leukemia Recurrent; Leukemia; Leukemia, MyeloidLast Updated:February 28, 2024Active, not recruiting
Condition(s):Lung Transplant; Hepatitis BLast Updated:October 4, 2023Recruiting
Condition(s):Acute Myeloid Leukemia; Leukemia; Leukemia, Myeloid; Myelodysplastic Syndromes; Myeloproliferative Neoplasm; Myeloproliferative DisordersLast Updated:February 28, 2024Recruiting
Condition(s):Hepatitis B, Chronic; Lipid DisorderLast Updated:June 1, 2022Enrolling by invitation
Condition(s):Efficacy; Safety; PharmacokineticsLast Updated:November 8, 2023Recruiting
Condition(s):Liver Cirrhosis; Hepatitis BLast Updated:July 28, 2015Unknown status
Condition(s):Tuberculosis, Multidrug-ResistantLast Updated:January 18, 2023Recruiting
Condition(s):Retinal Detachment; Rhegmatogenous Retinal DetachmentLast Updated:February 7, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.